Vir Biotechnology and Alnylam Pharmaceuticals Initiate Phase 1/2 Study of VIR-2218
Novel investigational RNAi therapeutic for the treatment of chronic hepatitis B virus (HBV) infection Subject dosing commenced SAN...
top of page
A L T I T U D E
Life Science Ventures
Companies in the News
bottom of page